University of Michigan

Children's Medical Center Corporation

University of Missouri

Henry Ford Health System

David Ginsburg

Gallia Levy

Han-Mou Tsai

Scott D Larsen

Hongmin Sun

Bryan Yestrepsky

Daniel Lawrence

Stuart H Orkin

Randal J Kaufman

Dell Paielli

Steven T Olson

Joseph D Shore

Jisong Cui

Daniel T Eitzman

Ann Marie Francis-Chmura

William P Fay

The present invention relates to chemical compounds, methods for their discovery, and their therapeutic and research use. In particular, the present invention provides compounds as therapeutic agents against bacterial infections (e.g., biofilms).

Methods and compositions for treating bacterial infection

Von Willebrand's Factor (VWF) is produced using an expression vector that includes: 1) a DNA sequence encoding a functional VWF protein; and 2) regulatory DNA capable of effecting expression of that DNA sequence in a host cell transformed with the vector. Restriction fragment length polymorphisms (RFLP's) associated with the VWF gene are identified and used in a probe for determining the source of a VWF gene in a DNA sample. The gene for VWF is localized to the short arm of human chromosome 12 (12p).

DNA encoding Von Willebrand Factor (VWF) and methods and cells for producing VFW, and VFW produced by the DNA, methods and cells

The present invention relates to chemical compounds, methods for their discovery, and their therapeutic and research use. In particular, the present invention provides compounds as therapeutic agents against bacterial infections.

The present invention relates to a disintegrin and metalloproteinase containing thrombospondin 1-like domains (ADAMTS) and in particular to a novel ADAMTS13 protease and to nucleic acids encoding ADAMTS13 proteases. The present invention encompasses both native and recombinant wild-type forms of ADAMTS13, as well as mutant and variant forms including fragments, some of which posses altered characteristics relative to the wild-type ADAMTS13. The present invention also relates to methods of using ADAMTS13, including for treatment of TTP. The present invention also relates to methods for screening for the presence of TTP. The present invention further relates to methods for developing anticoagulant drugs based upon ADAMTS13.

[object Object]

ADAMTS13 genes and proteins and variants and therapeutic compositions and methods utilizing the same

Methods and compositions for detecting variant ADAMTS13 genes

The present invention relates to compositions and methods for the screening of compounds for anticoagulant activity. In particular, the present invention relates to non-human transgenic animals expressing activated protein C ('APC')-resistant factor V proteins which display a predisposition toward spontaneous thrombosis. The present invention also provides methods for using these transgenic animals to screen compounds for anticoagulant activity.

Transgenic mice expressing APC resistant factor V

The invention relates generally to peptides which decrease the half-life of active plasminogen activator inhibitor-1. This invention further relates to methods and compositions for using peptides which decrease the half-life of active plasminogen activator inhibitor-1. Further, the invention includes methods and compositions useful in clot lysis.

Peptide mediated enhancement of thrombolysis methods and compositions

Growing community of inventors

Ann Arbor, MI, United States of America

David Ginsburg